Institutional Investors Recalibrate Positions in Cameco Stock

Cameco beats Q4 2025 earnings, signs major India supply deal. Major shareholders diverge, with some taking profits and others making aggressive new investments.

While Cameco's latest quarterly performance delivered strong results, a notable shift is occurring among its major shareholders. The landscape reveals a divergence in strategy, with certain funds securing profits and others making significant new commitments. Despite these portfolio adjustments, the underlying financial fundamentals present a compelling narrative for the uranium producer.

Geopolitical Momentum and Contract Wins

The long-term outlook for uranium suppliers continues to strengthen, supported by recent global developments. On March 16, Singapore and Japan inked an energy cooperation agreement centered on nuclear power and carbon-neutral technologies. This follows Cameco's own strategic move on March 2, when it finalized a long-term uranium supply contract with the Indian government. These events represent key pillars in the worldwide realignment of energy supply chains, providing structural tailwinds for the sector.

Quarterly Earnings Exceed Expectations

The company's financial report for the fourth quarter of 2025 served as a robust foundation. Cameco posted earnings per share of $0.36, notably surpassing the analyst consensus estimate of $0.29. Revenue climbed to $874.6 million, approximately 12% higher than the projected $782.1 million. The balance sheet remains sturdy, evidenced by a debt-to-equity ratio of just 0.14.

Market sentiment, as gauged by analysts, remains predominantly positive. Thirteen out of fifteen surveyed analysts maintain a "buy" or equivalent rating on the shares, even with a price-to-earnings ratio hovering around 111. Current price targets illustrate this confidence: CIBC has set a target of $202, while GLJ Research's stands at $171.20. The average target price across analysts is $150.40.

A Closer Look at Shareholder Activity

Institutional ownership remains high, accounting for roughly 70% of the company's outstanding shares. However, recent filings show contrasting maneuvers by major holders.

On the selling side, AllianceBernstein and Crawford Investment Counsel have trimmed their stakes. Crawford Investment Counsel reduced its position by 23%, a move involving the sale of 13,554 shares. Market observers largely interpret this activity as profit-taking following a substantial rally in the share price.

Conversely, other institutions are aggressively expanding their exposure. Kadensa Capital Ltd. dramatically increased its holding by 3,244% during the third quarter of 2025. In another significant position, UBS Asset Management currently holds over 600,000 shares, with a market value approaching $25 million.

Market Context and Trajectory

Cameco's share price is currently in a phase of consolidation. Over the preceding twelve-month period, the stock has traded within a wide range of $35.00 to $135.24. The substantial institutional participation and the ambitious analyst price targets collectively signal that confidence in the uranium sector and in Cameco specifically remains resilient, even amidst these portfolio reallocations. The mixed activity among large investors underscores a market weighing strong fundamentals against valuation after a significant advance.